Neonatal atypical hemolytic uremic syndrome from a factor H mutation treated with eculizumab

Background: Atypical hemolytic uremic syndrome (aHUS) results from an inherited dysregulation of the alternative complement pathway leading to thrombotic microangiopathy consisting of hemolytic anemia, thrombocytopenia, and renal injury. The complement inhibitor eculizumab is an approved treatment,...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Sheena, Pradhan, Madhura, Meyers, Kevin E.C., Le Palma, Krish, Laskin, Benjamin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dustri-Verlag Dr. Karl Feistle 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839031/
https://www.ncbi.nlm.nih.gov/pubmed/25816809
http://dx.doi.org/10.5414/CN108532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839031/
https://www.ncbi.nlm.nih.gov/pubmed/25816809
http://dx.doi.org/10.5414/CN108532

Ejemplares similares